XIGDUO Extended Release (XR) (DAPAGLIFLOZIN/METFORMIN XR FDC) Regulatory Postmarketing Surveillance To Observe Safety and Effectiveness Of XigduoXR (Registered) In Korean Patients
Phase of Trial: Phase IV
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Dapagliflozin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Acronyms XigduoPMS
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 28 May 2018 Planned number of patients changed from 600 to 750.
- 03 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Jan 2020.